Skip to main content
. 2011 Sep 12;16(9):407–410. doi: 10.1186/2047-783X-16-9-407

Table 1.

Patient characteristics, asthma-related quality of life (AQLQ), atopic dermatitis related quality of life (DLQI), and asthma-related treatment at baseline and after 6 and 12 months omalizumab therapy

Asthma Asthma + atopic dermatitis P value
n 13 9
Age (years) 47.5 ± 14.8 38.1 ± 11.3 0.127
Sex /female) 10/13 77% 6/9 67% 0.394
IgE 212 ± 224 3528 ± 2723 < 0.001
FEV1 71.5 ± 10,7 76.2 ± 7,4 0.350
Weight in kg 82.3 ± 22.0 76.3 ± 16.1 0.472
Omalizumab dosage
(mg/2 weeks) 213 ± 86 233 ± 109 0.654
OCS baseline 12/13 7/9 0.394
OCS 6 month 4/13 0/9 0.003
OCS 12 month 4/13 0/9 0.003
AQlQ baseline 102 ± 40 143 ± 44 0.041
AQlQ 6 month 148 ± 48 175 ± 40 0.041
AQlQ 12 month 152 ± 45 170 ± 42 0.04
DlQI baseline 19 ± 10
DlQI 6 month 7 ± 8
DlQI 12 moth 6 ± 6

OCS, oral corticosteroids, ICS, inhaled corticosteroids.

HHS Vulnerability Disclosure